Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe

Outlook Therapeutics, Inc.

2026-Q1 EPS reported -$0.38

Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.
Adjusted net loss $13.5M ($0.22/share) vs adjusted net loss $21.6M ($0.89/share) a year ago.
Revenue negatively impacted by returns reserve for short-dated product from UK distributor; unit sales more than doubled QoQ.
Cash and equivalents $8.7M as of Dec 31, 2025 (excluding $2.4M ATM proceeds post-quarter).
Submitted Type A meeting request to FDA to discuss ONS-5010 CRL for wet AMD; additional EU launches planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.